Advertisement

Dr. Stevenson on Potential of Immunotherapy in Squamous NSCLC

Published on: 

In Partnership With:

Partner | Cancer Centers | <b>Cleveland Clinic</b>

James Stevenson, MD, medical oncologist at Cleveland Clinic, discusses the potential of immunotherapy agents as treatment for patients with squamous non–small cell lung cancer (NSCLC).

Advertisement

James Stevenson, MD, medical oncologist at Cleveland Clinic, discusses the potential of immunotherapy agents as treatment for patients with squamous non—small cell lung cancer (NSCLC).

Stevenson predicts that the landscape of squamous NSCLC will be completely different in the coming years, especially in the frontline setting. Here, immunotherapy may more often be a first choice by oncologists compared with chemotherapy. Additionally, combination therapies with chemotherapy plus monoclonal antibodies, such as necitumumab (Portrazza), will also likely be given as a later-line treatment for patients.

Further research will help oncologists decide on the first-, second-, and third-line regimens for squamous NSCLC, as well as their own clinical experience, Stevenson adds.


Advertisement
Advertisement